ArticleCentral-European journal of immunology2025
Long non-coding RNA GAS5 alleviates inflammation in acute gouty arthritis
Article in Central-European journal of immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Growing evidence suggests that long non-coding RNA (lncRNA) GAS5 plays a critical role in inflammatory responses such as arthritis. In this study, we explored the function of GAS5 in acute gouty arthritis (AGA) and elucidated how GAS5 acts. Material and methods: RT-qPCR was used to examine GAS5 expression levels in serum. Receiver operating characteristic (ROC) curve analysis was used to explore the diagnostic value of GAS5. The THP-1 cell model of AGA was established by monosodium urate (MSU) in vitro. The pro-inflammation cytokines interleukin (IL)-1 Results: GAS5 was suppressed in AGA patients, accompanied by upregulation of miR-485-5p. A high correlation between GAS5 and miR-485-5p was found, and GAS5 was associated with clinical characteristics in varying degrees. GAS5 achieved excellent performance accuracy, with the area under the ROC (AUC) of 0.915. Additionally, MSU-induced inflammatory responses were relieved through the overexpression of GAS5 in the cell model, while miR-485-5p overexpression reversed the responsiveness. The link between miR-485-5p and GAS5 was established in MSU-induced THP-1 macrophages. Conclusions: In summary, GAS5 alleviated MSU-induced excessive inflammation in THP-1 macro- phages by targeting miR-485-5p, suggesting that GAS5 is a potential diagnostic biomarker for AGA treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.